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A B S T R A C T
Fibronectin (FN) occurs as both a soluble form, in plasma and at sites of tissue injury, and a cellular form in
tissue extracellular matrices (ECM). FN is critical to wound repair, ECM structure and assembly, cell adhesion
and proliferation. FN is reported to play a critical role in the development, progression and stability of cardi-
ovascular atherosclerotic lesions, with high FN levels associated with a thick ﬁbrotic cap, stable disease and a
low risk of rupture. Evidence has been presented for FN modiﬁcation by inﬂammatory oxidants, and particularly
myeloperoxidase (MPO)-derived species including hypochlorous acid (HOCl). The targets and consequences of
FN modiﬁcation are poorly understood. Here we show, using a newly-developed MS protocol, that HOCl and an
enzymatic MPO system, generate site-speciﬁc dose-dependent Tyr chlorination and dichlorination (up to 16 of
100 residues modiﬁed), and oxidation of Trp (7 of 39 residues), Met (3 of 26) and His (1 of 55) within selected
FN domains, and particularly the heparin- and cell-binding regions. These alterations increase FN binding to
heparin-containing columns. Studies using primary human coronary artery smooth muscle cells (HCASMC) show
that exposure to HOCl-modiﬁed FN, results in decreased adherence, increased proliferation and altered ex-
pression of genes involved in ECM synthesis and remodelling. These ﬁndings indicate that the presence of
modiﬁed ﬁbronectin may play a major role in the formation, development and stabilisation of ﬁbrous caps in
atherosclerotic lesions and may play a key role in the switching of quiescent contractile smooth muscle cells to a
migratory, synthetic and proliferative phenotype.
1. Introduction
Fibronectin (FN) is a large plasma and extracellular matrix glyco-
protein, composed of two nearly identical subunits (~ 230–270 kDa)
linked by two disulﬁde-bonds located near the carboxyl termini [1,2].
The protein exists in two forms: a soluble form predominantly found in
plasma, but also in abundance at sites of tissue injury, and a cellular
form present in tissue extracellular matrix (ECM). The plasma form
plays a key role in the early physiological responses to tissue injury as it
binds to ﬁbrin ﬁbres via multiple domains and hence is a key compo-
nent of blood clots [3]. The resulting ﬁbrin-FN network supports mi-
gration and adhesion of ﬁbroblast and endothelial cells which over time
replace this provisional matrix structure with cell-derived FN, collagen,
laminins and other ECM components [4,5]. Cell-derived FN, which is
synthesized by endothelial, smooth muscle and ﬁbroblast cells, amongst
others, is structurally-related to the plasma form, but also contains extra
domains (extra domains A and B) which are alternatively spliced type
III modules that are not present in the plasma form [6].
FN is present in the ECM of the arterial wall under normal physio-
logical conditions [7], but a signiﬁcant increase in concentration, and
diﬀerent isoforms, have been reported in atherosclerotic lesions [8];
these changes appear to occur during lesion development [9]. Patients
with coronary artery disease also have elevated levels of plasma FN
[10]. These changes may be associated with remodelling of the vascular
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wall during the development of atherosclerosis, with considerable evi-
dence for increased ECM deposition in the ﬁbrous caps of athero-
sclerotic plaques [11]. The formation of a thick ﬁbrous cap is widely
regarded as being beneﬁcial with regard to plaque stability [11].
Rupture of the lesion, exposure of the highly thrombogenic substrata,
and subsequent thrombus formation, is a major cause of heart attacks
and strokes [11]. Rupture prone plaques typically have a thin ﬁbrous
cap, increased numbers of activated inﬂammatory cells capable of
producing oxidants, high levels of lipids, and low numbers of smooth
muscle cells [12,13]. Rupture occurs most commonly in the shoulder
regions where macrophages and other leukocytes accumulate [14,15].
Studies on atherosclerosis-prone apo E-/- mice that do not express
plasma-derived FN, have shown a reduction in number and size of
atherosclerotic lesions, however mice deﬁcient in plasma-derived FN
lacked vascular smooth muscle cell inﬁltration and failed to develop a
ﬁbrous cap [16]. These data are consistent with the hypothesis that FN
plays a critical role in generating and stabilizing the ﬁbrous cap of
atherosclerotic lesions, and plays a major role in determining lesion
stability and propensity to rupture. The colocalization of inﬂammatory
cells with FN in plaque shoulder regions, and FN degradation during the
progression of atherosclerosis, supports the hypothesis that plaques are
damaged and destabilized by inﬂammatory cell oxidants, with this
occurring, at least in part, via ECM damage [17,18].
Oxidants are intentionally generated during many physiologic and
pathological processes [19]. Activated leukocytes generate superoxide
radicals (O2•-) and hydrogen peroxide (H2O2) via NADPH oxidase
(NOX) enzymes, and neutrophils, monocytes and some tissue macro-
phages release the heme enzyme myeloperoxidase (MPO) from in-
tracellular storage granules [20]. In the presence of chloride ions (Cl-),
MPO utilizes H2O2 to generate the potent oxidant hypochlorous acid
(HOCl) [20,21]. HOCl reacts rapidly with many biological targets, with
kinetic data indicating that proteins are major targets, due to their
abundance and high reactivity [21,22]. Although HOCl plays an im-
portant role in killing invading pathogens, excessive or misplaced
generation can result in host tissue damage, with this being associated
with multiple human pathologies involving acute or chronic in-
ﬂammation, including atherosclerosis [21,23–25].
There is limited data on HOCl-induced modiﬁcations to isolated FN,
or FN in the arterial wall, though it is known that FN can be modiﬁed by
HOCl both in vitro, and in basement membrane preparations from other
tissues [26–28]. Modiﬁed FN colocalizes with leukocyte-derived MPO
in human atherosclerotic lesions [29], but the nature of the modiﬁca-
tions induced on FN by MPO-derived oxidants are unknown. Sulfur-
containing amino acids (Cys, Met and cystine) are major targets for
HOCl [22,30,31], however FN has low levels of Cys, though a large
number of Met and disulﬁde (cystine) bonds; these are therefore likely
to be major targets, if they are accessible. HOCl can also modify His,
Trp, Lys and Tyr residues [22] though the chloramines (RNHCl species)
formed on His and Lys have limited stability and hence cannot be easily
quantiﬁed in vivo [32,33]. Reaction of HOCl and chloramines with Tyr
generates the well-established biomarker 3-chlorotyrosine (3Cl-Tyr)
[34–36]. This stable product is characteristic of MPO-mediated da-
mage, as it is the only enzyme known to induce signiﬁcant levels of
chlorination [35]. Elevated 3Cl-Tyr levels have been detected on low-
and high-density lipoproteins extracted from atherosclerotic lesions,
and also on plasma proteins from people with cardiovascular disease
[36–40].
The studies reported here aimed to determine whether human
plasma FN is susceptible to damage induced by HOCl and a MPO-cat-
alysed system, to identify the nature and sites of damage using a re-
cently developed proteomics approach [41], and to examine whether
oxidant-modiﬁed FN has functional eﬀects on human coronary artery
smooth muscle cells, a key cell type within the artery wall.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma Aldrich except for:
human plasma ﬁbronectin (FN) (Corning or Sigma-Aldrich), human
myeloperoxidase (Planta Natural Products), lysyl endopeptidase (Lys-C)
(Wako), and 3-chloro-[13C6] tyrosine (Cambridge Isotope Laboratories).
All solvents were HPLC or LCMS grade. RNA was extracted from cell
cultures using an RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturers protocol, with cDNA synthesis and quantitative real-
time PCR carried out using SuperScript™ III First-Strand Synthesis
SuperMix (Invitrogen) and SYBR® GreenER™ qPCR SuperMix Universal
(Invitrogen), respectively. Human interleukin-6 (IL-6) was determined
using an ELISA kit (Biolegend; San Diego, USA) as described by the
manufacturer. Human coronary artery smooth muscle cells (donor
1596), SMC growth medium and SMC basal medium were from Cell
Applications (San Diego, USA).
2.2. Quantiﬁcation of HOCl formation using 3,3′,5,5′-tetramethylbenzidine
(TMB) or monochlorodimedone (MCD)
TMB was used to quantify HOCl production by the MPO-H2O2-Cl-
system as outlined previously [42]. The developing reagent consisted of
20mM TMB in dimethylformamide, and 2mM NaI in sodium acetate
buﬀer (0.44M, pH 5.4) prepared immediately prior to use. The MPO-
H2O2-Cl- (20 nM MPO, 0–200 μM H2O2, 200mM Cl-) or reagent HOCl
(0–200 μM) was incubated with taurine (10mM) at 37 °C for 2 h. Then,
50 μL of TMB reagent was added to each well and incubated for 5min at
21 °C. The absorbance at 645 nm was then measured on a Spectra Max®
i3x microplate reader. The concentration of HOCl formed and trapped
by taurine, was calculated using a standard curve generated using re-
agent HOCl (0–200 μM). HOCl production was also quantiﬁed by de-
termining the loss of parent MCD spectrophotometrically, using a molar
extinction coeﬃcient ε290 17,700M−1 cm−1 [43].
2.3. Oxidation of human plasma ﬁbronectin (FN)
Puriﬁed FN was prepared in 100mM sodium phosphate buﬀer, pH
7.4, at a concentration of 1mgmL−1 (2.27 μM). HOCl was added at 0,
100 or 500 μM and incubated for 1 h at 21 °C. HOCl stocks were
quantiﬁed spectrophotometrically at 292 nm using a molar extinction
coeﬃcient (ε292) of 350M−1 cm−1. For MPO-mediated oxidation, ali-
quots of FN were incubated (unless otherwise indicated) with 0.1 μM
MPO, 100mM NaCl and 500 μM H2O2, with the H2O2 added as
10× 50 μM aliquots at 10min intervals at 37 °C on a thermo-shaker,
and incubated for a further 10min after the ﬁnal addition. Controls
with no MPO, no H2O2, no NaCl, and untreated FN were included.
2.4. Protein digestion for mass spectrometry
Modiﬁed and non-modiﬁed proteins were digested in-solution using
an optimised protocol without the use of reduction and alkylation, as
these reduce the yield of chlorinated products (T. Nybo, M.J. Davies, A.
Rogowska-Wrzesinska, unpublished data). Brieﬂy, residual reactants
and salts were removed using 10 kDa spin-ﬁlters (Amicon Ultra-0.5
Ultracel-10K, Merck Millipore, Ireland), with buﬀer exchange into
50mM triethyl ammonium bicarbonate buﬀer supplemented with 4M
urea and 1% sodium deoxycholate (SDC) to induce denaturation.
Proteins were incubated for> 3 h, followed by a two-step digestion
using Lys-C for 2 h in 4M urea, followed by trypsin for 18 h in 1M urea.
The temperature was kept at 30 °C to minimize protein carbamylation.
SDC was removed using acidiﬁcation and ethyl acetate phase transfer as
described previously [44].
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2.5. Mass spectrometry analysis of treated samples
One μg of peptide mixture was separated using a precolumn (5 µm
particle size, C18 fused silica beads, 4 cm × 100 µm ID) coupled to an
analytical column (3 µm particle size, C18 fused silica beads, 20 cm ×
75 µm ID) mounted on an EASY nLC 1000 instrument (Thermo Fisher
Scientiﬁc, Germany). Peptides were separated at a ﬂow rate of 250 nL
min−1 using buﬀer A (0.1% formic acid) with 5–38% buﬀer B (0.1%
formic acid, 90% acetonitrile), over a 60min linear gradient, followed
by an 8min wash, using increasing concentrations of buﬀer B
(38–100%), and 5min of 100% buﬀer B. Eluting peptides were ana-
lysed on a QExactive HF (Thermo Fisher Scientiﬁc) mass spectrometer
in positive ion mode using data-dependent acquisition. Full scans of m/
z 400–1400 was recorded with 120,000 resolution, with the top 12
most intense ions selected for higher energy collisional dissociation
(HCD) fragmentation at a normalised collision energy of 28. Blanks
were run between each sample to monitor and prevent carry-over.
2.6. Relative quantiﬁcation of oxidative modiﬁcations by mass spectrometry
Mass spectrometry results (.raw, Xcalibur data ﬁles) were imported
and analysed using Progenesis QI for proteomics (Nonlinear Dynamics,
USA). Database searches were carried out using Proteome Discoverer
2.1 against a FN isoform database. For MPO-mediated oxidations, MPO
isoform sequences were included in the database. The following search
parameters were used: parent ion tolerance - 4 ppm; fragment ion tol-
erance - 0.1 Da; trypsin - 2 missed cleavages allowed; ﬁxed modiﬁca-
tions – none; variable modiﬁcations: Cl (Y, W), 2 x Cl (Y, W), 1 x O (M,
H, C, W), 2 x O (M, C, W), 3 x O (C). The results were exported as
pepXML ﬁles and imported back into Progenesis. Peptide measurements
were exported from Progenesis providing normalised abundance cal-
culated from the extracted ion chromatograms of precursor ions [45].
All identiﬁcations were validated by manual inspection of fragment ion
spectra and chromatograms. For chlorinated peptides, the isotopic
distribution was inspected relative to the native peptide to conﬁrm the
characteristic enhancement of the 3rd isotopic isomer arising from the
presence of chlorine isotopes [46]. Quantitative values from diﬀerent
charge states were pooled manually. Zero-values from Progenesis were
handled in two ways: a) if missing in all replicates, the abundance was
assumed to be below the detection limit and for calculation purposes
their value was set to 1; b) if missing in 1 replicate but present in the
remaining, it was assumed to be randomly missing and removed. The
relative site occupancy for modiﬁcation of a particular amino acid was
calculated by dividing the sum of signal intensities (area-under-the-
curve) of all peptide spectral matches containing the modiﬁed position,
with the sum of the intensity of all peptide spectral matches containing
the position (non-modiﬁed and modiﬁed) with the values expressed as a
percentage.
2.7. Quantiﬁcation of total 3-chlorotyrosine levels
Protein samples (25 µg) were precipitated with trichloroacetic acid
(TCA; w/v 8%) and spiked with 3-chloro-[13C6]tyrosine (100 pmol,
internal standard) before evaporation using a centrifugal vacuum con-
centrator for 1 h, as described previously [47]. MS experiments using
spin ﬁlters versus TCA/acetone precipitation for protein puriﬁcation
showed that the use of TCA did not induce artefactual chlorination (T.
Nybo, M.J. Davies, A. Rogowska-Wrzesinska, unpublished data). The
resulting pellet was hydrolysed overnight in 4M methanesulfonic acid
(MSA, 50 μL) under vacuum at 110 °C. Amino acids were partially
puriﬁed by solid-phase extraction using 1mL C-18 cartridges (Supelco).
The columns were activated using 100% methanol (1 mL), followed by
equilibration with 0.1% triﬂuoroacetic acid (TFA) in water (2× 1mL).
Samples were diluted with 1% TFA in water (10 μL hydrolysate in
400 μL of 1% TFA) in order to improve ion-pairing and subsequent
binding of amino acids to the C18 material. The samples were loaded
onto the column and washed with 0.1% TFA in water (1× 1mL) fol-
lowed by elution with 50% methanol containing 0.1% formic acid
(1×1mL). Extracts were dried at 60 °C under vacuum for 4 h and
dissolved in 50 μL of 0.1% formic acid.
3-Chlorotyrosine (3-ClTyr) was quantiﬁed by electrospray ionisa-
tion LC-MS in the positive ion mode using a Bruker Impact HD II mass
spectrometer. Samples were separated by gradient elution using a
Phenomenex Aeris™ 2.6 µm PEPTIDE XB-C18 250× 2.1mm HPLC
column. Elution was started at 3% B for 1min, followed by gradient
elution from 3% to 50% B over 9mins, 50–80% B over 2min, followed
by isocratic elution using 80% B for 3mins, before decreasing to 3% B
over 2mins and re-equilibration at 3% B for 3min. Buﬀer A consisted of
0.1% formic acid in H2O and buﬀer B consisted of 90% acetonitrile in
H2O. The electrospray needle was held at 4500 V, with end plate oﬀset
of 500 V and temperature of 200 °C. Nitrogen gas was used for both the
nebuliser (2.0 bar) and as the dry gas (8.0 Lmin−1). An external stan-
dard curve was generated for 3-ClTyr with a concentration range of
78 fmol to 20 pmol loaded onto the column, with the internal standard
maintained at 4 pmol. A linear response of 3-ClTyr relative to the in-
ternal standard was observed over this concentration range. Standards
were prepared in 0.1% formic acid in H2O. Spectra were collected in
MS1 mode and quantiﬁcation performed on extracted ion chromato-
grams for 3-ClTyr (m/z=216.04) and 3-Cl[13C6]Tyr (m/z=222.06).
2.8. Heparin-aﬃnity chromatography
FN (100 μg) was loaded onto a HiTrap Heparin High Performance
column (GE Healthcare, UK) on a Äkta FPLC system (GE Healthcare,
UK) using 10mM sodium phosphate buﬀer pH 7.4 at a ﬂow rate of
1mLmin−1. Elution was carried out using a 10min gradient from 0%
to 100% of 100mM NaCl in 10mM sodium phosphate buﬀer, pH 7.4.
Protein elution was monitored by UV detection.
2.9. Cell culture
Primary human coronary artery smooth muscle cells (HCASMC)
were cultured in vitro using commercial smooth muscle cell (SMC)
growth medium in a humidiﬁed incubator containing 5% CO2 at 37 °C.
HCASMC were cultured for 1 week with an initial density of 104 cells in
200 μL of medium in 96-well plate, or at 2×104 cells in 500 μL of
medium in 8-well tissue culture slides, or 106 cells in 25mL medium in
T175 ﬂasks. The growth medium was replaced three times per week.
2.10. Adhesion of human coronary artery smooth muscle cells (HCASMC)
to native and modiﬁed FN
Adhesion of HCASMC to native or modiﬁed FN was assessed using
black 96-well tissue culture plates pre-coated overnight with puriﬁed
FN (20 μgmL−1, ~ 44 μM). The plate was then treated with 50 μL of
HOCl (1–200 μM) or a MPO-H2O2-Cl- system (20 nM MPO, 1–200 μM
H2O2, 200mM Cl-) for 2 h at 37 °C. The plate was then rinsed twice with
sterile PBS to remove any excess oxidant or the enzyme system, before
blocking with sterile and heat-denatured 1% BSA in PBS (w/v) at 37 °C
for 1 h to minimize non-speciﬁc binding of cells to the plastic. The
HCASMC (5× 106 cells mL−1) were pre-loaded before use with 5 μM
calcein AM for 30min at 37 °C, with the cells subsequently washed with
pre-warmed basal medium to remove residual dye. The calcein AM-
labelled HCASMC were then added at a concentration of 104 cells per
well to the plates containing native or modiﬁed FN, and incubated in a
tissue culture incubator for 90min. The plates were then rinsed twice
with PBS (containing Ca2+ and Mg2+) to remove non-adherent cells.
Fluorescence from the adherent cells was then quantiﬁed using a
SpectraMax® i3x microplate reader, with λex 490 nm and λem 520 nm,
respectively. Alternatively, adhesion of HCASMC to modiﬁed FN was
carried out on 8-well glass slides. These were coated with FN, treated
with HOCl (20 or 100 μM), washed, and incubated with HCASMC
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(2× 104 cells per well) as described above. Adherent cells were rinsed
twice with PBS and then ﬁxed with 4% formaldehyde in PBS (37 °C,
15 min) then permeabilized using 0.5% (v/v) Triton X-100 in PBS on ice
for 5min. The slides were rinsed again with PBS and counterstained
with ActinRed 555 (Life Technologies) and 1 μgmL−1 DAPI in PBS in
the dark at 21 °C for 30min to stain F-actin and nuclei, respectively.
The cells were then rinsed three times with PBS, air dried, had cover
slips added, and examined under a ﬂuorescence microscopy (Olympus,
Japan). Alternatively the permeabilized HCASMC (as above) were
stained with 0.4% trypan blue for 15min at 21 °C, to examine cell
morphology using bright ﬁeld microscopy.
2.11. Proliferation of HCASMC on native and modiﬁed FN
Black 96-well tissue culture plates coated with native or modiﬁed
FN were prepared as described above, except the FN was treated with
1 μM HOCl at 37 °C for 2 h. The plates were then rinsed (2 × PBS) to
remove residual HOCl, and then blocked with sterile and heat-dena-
tured 1% (w/v) BSA in PBS (Ca2+ and Mg2+ -free) at 37 °C for 1 h to
minimize non-speciﬁc binding. HCASMC were pre-loaded with 5 μM
calcein AM (as above), and then added (104 cells per well) to the native
or treated FN and incubated for 90min. The plates were then rinsed (as
above) to remove non-adherent cells. The initial (day 0) density of
adherent cells was quantiﬁed by ﬂuorescence as described above. The
plates were then washed twice with PBS (with Ca2+ and Mg2+) and
replaced with 200 μL of growth medium, then incubated for 48 h in an
incubator. The ﬁnal cell population (day 2) was determined using the
MTS assay: 20 μL of MTS reagent was added to each well and incubated
for 4 h. The samples were then transferred to a clear tissue culture plate,
and the absorbance at 490 nm measured using a SpectraMax® i3x mi-
croplate reader.
2.12. Real-time PCR
Quantitative real time PCR was used to examine mRNA transcrip-
tion proﬁles in HCASMC incubated on native FN, or FN treated with
HOCl (1, 10, 50 μM). Multiple genes involved in cell mitosis, the in-
ﬂammation response, and ECM synthesis and turnover were examined.
Total RNA was extracted from HCASMC after 48 h incubation on native
or HOCl-treated FN using an RNeasy Mini Kit (Qiagen). The RNA
concentration and purity was quantiﬁed spectrophotometrically using a
SpectraMax® i3x microplate reader. RNA (400 ng) was used for single
strand cDNA synthesis using a cDNA RT kit in a total volume of 20 μL
containing 1×RT reaction mix, 10×RT Enzyme Mix, and 2 U RNase
H. Conditions for the reverse transcription reactions were as follow:
25 °C for 10min, 50 °C for 30min and 85 °C for 5min. Real-time PCR
was carried out on ABI 7900 HT machine with 20 μL reaction mix buﬀer
containing 10 μL SYBR® GreenER™, 2 μL of each primer at 10 pmol/μL,
0.4 μL of ROX reference dye and 2 μL of cDNA. Commercial primers
were ordered form Qiagen without deﬁnite primer sequence (IL-6, TNF-
α, COX-2, iNOS, IL-1β, FN1, COL4A1, LAMA1, LAMA5, LAMB2), other
primers were also used (5′-3′): PCNA (F: AGGCACTCAAGGACCTCA
TCA; R: GAGTCCATGCTCTGCAGGTTT), CCNA1 (F: GCACCCTGCTCG
TCACTTG; R: CAGCCCCCAATAAAAGATCCA), CCNB1 (F: AGCTGCTG
CCTGGTGAAGAG; R: GCCATGTTGATCTTCGCCTTA), LAMA2 (F: GTT
CCAGGGCATTTGTGTGA; R: TAGATGCTGGGTTTGGGCTTT),MMP1 (F:
CGCACAAATCCCTTCTACCC; R: GGACTTCATCTCTGTCGGC), MMP11
(F: TCTACTGGAAGTTTGACCCTGTG; R: GTCAGAGGAAAGTGTTGG
CAG), MMP13 (F: TTTTTCAACGGACCCATACAGTT; R: TTACCCCAAA
TGCTCTTCAGG), ADAMTS1 (F: CTTGTGGCAGACCAGTCGAT; R: TTC
ACCACCACCAGGCTAAC), TIMP2 (F: TACACACGCCAATGAAACCGA;
R: GGTTGCCGCTGAATAGAACA). β-actin (F: GATTCCTATGTGGGCGA
CGA; R: AGTTGGTGACGATGCCGTG) was used as house-keeping gene.
Triplicate wells were used and data analysis was carried out using the 2-
ΔΔCT method.
2.13. Statistics
Statistical analysis of MS data was performed by Student's t-test
using SAS Enterprise Guide 7.1 (SAS Inc., USA). For other analyses, one-
way ANOVA and Student's t-tests were performed on IBM SPSS 19.0 to
examine statistical signiﬁcance. Experiments were performed in tripli-
cate and P < 0.05 was considered signiﬁcant.
3. Results
3.1. Hypochlorous acid induces chlorination and oxidation of human
plasma FN
To investigate the eﬀect of MPO-derived HOCl on human plasma
FN, samples of the protein were treated with either reagent HOCl (bolus
addition of 0, 100, and 500 μM) or an MPO-H2O2-Cl- enzymatic system
with 500 μM H2O2. Modiﬁed and control samples were analysed by
peptide mass mapping using mass spectrometry without reduction or
alkylation as these interfere with the detection and quantiﬁcation of
some modiﬁcations, particularly chlorinations ([48]; T. Nybo, M.J.
Davies, A. Rogowska-Wrzesinska, unpublished data). As no reduction
step was employed, disulﬁde-linked peptides remain in the digestion
mixture, resulting in a decreased overall coverage of the protein se-
quence. The disulﬁde-rich domains of FN (Heparin/Fibrin I, Collagen,
and Fibrin II) account for the majority of the missing sequence cov-
erage, with the total coverage being ~ 66% in untreated control sam-
ples (Fig. 1). In contrast, near complete coverage was obtained for the
DNA-, Cell-, and Heparin II- binding domains (Fig. 1).
Treatment of FN with 100 and 500 μM HOCl resulted in the detec-
tion of multiple modiﬁcations (Table 1, Supplementary Tables 1,2),
with only species detected in at least two out of three experimental
treatments, and none of the controls, reported. A greater number, and a
higher extent of modiﬁcation, was detected with 500 μM HOCl com-
pared to the control, or 100 μM treatment (Supplementary Figs. 1–5).
Thus, with the lower oxidant dose, 6 modiﬁcations were detected at 6
diﬀerent sites within the covered sequence, whereas with 500 μMHOCl,
25 modiﬁcations were observed. In some cases, multiple modiﬁcations
were detected within a single peptide (e.g. at Met, M, or Tyr, Y, in the
peptide: VTIMWTPPESAVTGYR), or as a result of both mono- and di-
chlorination of a Tyr residue at a single site (e.g. at the ﬁrst Tyr in the
peptide: IYLYTLNDNAR). Three major types of modiﬁcation were de-
tected: oxidation of Met residues (3 sites: Met-926, Met-1783, Met-
2050) to give an m/z+16 species assigned to the sulfoxide, oxidation
at Trp residues (5 sites: Trp-927, Trp-1195, Trp-1468, Trp-1742, Trp-
1923) to give an m/z+16 species, and mono- or di-chlorination at Tyr
residues (16 sites: see Table 1). With the 100 μM treatment only
monochlorination (to give 3-ClTyr) at Tyr was detected, whereas with
the 500 μM dose, dichlorination to give 3,5-Cl2Tyr was detected at two
speciﬁc Tyr residues (Tyr-687 and Tyr-1882). In these cases mono-
chlorination was detected at the lower HOCl dose, suggesting that these
Fig. 1. Coverage map obtained for human plasma FN (2.27 μM) treated with 0, 100, and 500 μM HOCl. Dark grey: detected sequence; light grey: missing sequence.
Total sequence length: 2386 amino acids, with 66% coverage. Red bars indicate position of disulﬁde bonds. Known functional domains on the protein are indicated
by boxes.
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residues are particularly prone to modiﬁcation.
Treatment with the MPO-H2O2-Cl- system, using 500 μM H2O2, also
resulted in the detection of multiple modiﬁcations (Table 1). This
system gives near stoichiometric conversion of H2O2 to HOCl, as as-
sessed by either the MCD or TMB assays (Supplementary Fig. 6). The
modiﬁcations induced by the enzyme system reproduced some, but not
all, of the modiﬁcations detected with the 500 μMHOCl system. Thus, 8
of the 3-ClTyr, and 1 of the 3,5-Cl2Tyr, sites were reproduced. For Met
oxidation, one site was reproduced (Met-1783), but two Trp oxidation
sites (Trp-65, Trp-484) and one His (His-689) oxidation (m/z+16)
were also detected.
In some cases, multiple modiﬁcations were detected in close
proximity within particular peptides, or regions of the sequence. Thus,
Fig. 2 shows the fragment ion spectra of the peptide 923VTIMWTPPE-
SAVTGYR938 which was detected with modiﬁcations (oxidations) at
Met-926 and Trp-927, and chlorination at Tyr-937. This cluster of da-
mage was not detected with the MPO-H2O2-Cl- system. These mod-
iﬁcations occurred both independently, producing peptide forms with
each modiﬁcation individually, and also as co-occurring species. The
site assignment of the oxidation is determined by a + 16 Da mass shift
on either fragment ion y12 for Trp-927 or y13 for Met-926. Observation
of predominantly no-mass shift y12 and a lower abundance of the mass
shifted y12-ion indicate that Trp-927 is modiﬁed to some extent, but
Met-926 is the primary target.
Quantiﬁcation of the extent of modiﬁcation at particular sites was
assessed by determining the relative site occupancy (RSO). Overall, FN
was modiﬁed to a lesser extent by the MPO enzymatic system when
compared to the 500 μM reagent HOCl system, both in number of sites
and in relative site occupancy. A number of these modiﬁcations occur in
functionally-important domains (Fig. 3). Thus, oxidation of Met-1783
was detected with both 500 μM HOCl and the MPO-H2O2-Cl- system,
and to a lesser extent with 100 μM HOCl (Fig. 4A and C). For Tyr-1882,
3-ClTyr was observed with 100 μM HOCl, while at 500 μMHOCl further
chlorination to form 3,5-Cl2Tyr was detected, as well as signiﬁcantly
higher levels of 3-ClTyr (Fig. 4B and D). Interestingly, no chlorination
was observed on the nearby Tyr-1884 residue. Summation of all of the
relative site occupancy data for 3-ClTyr formation gives values of ~1.3,
~ 22.1 and ~ 3.2 for the 100 μM HOCl, 500 μM HOCl and MPO enzy-
matic systems respectively. Inclusion of all the observed modiﬁcations
(i.e. chlorination at Tyr and oxidations at Met, Tyr, His and Trp) gives
values of ~ 20.6, ~ 110.0 and ~ 20.7 for the 100 μM HOCl, 500 μM
HOCl and MPO systems respectively.
3.2. Quantiﬁcation of total 3-chlorotyrosine
The total extent of 3-ClTyr formation with reagent HOCl was de-
termined by complete hydrolysis of the native and modiﬁed proteins by
acid hydrolysis, and subsequent separation and quantiﬁcation of the
released 3-ClTyr by LC-MS, using an isotope-labelled product as an
internal standard [47]. Under the conditions used the concentration of
3-ClTyr detected on the untreated protein was ~ 9.7 μmoles 3-ClTyr per
mole protein, and ~ 0.97mmoles 3-ClTyr per mole parent Tyr, based on
the presence of 100 Tyr residues in parent FN. Treatment of the FN with
100 μM HOCl increased the 3-ClTyr levels ~ 30-fold (i.e. ~ 28.5
mmoles 3-ClTyr per mole parent Tyr), and treatment with 500 μMHOCl
increased the 3-ClTyr levels 141-fold (i.e. ~ 137 mmoles 3-ClTyr per
mole parent Tyr). These correspond to % conversions (after subtraction
of control values) of ~ 2.8 and ~ 13.7 for 3-ClTyr formation from the
Table 1
Nature and sites of modiﬁcations induced by reagent HOCl (100 or 500 μM), or a MPO/H2O2/Cl- system with 500 μM H2O2. Modiﬁed residue(s) are indicated in bold
in the peptide sequence. Numbering is from the gene sequence with amino acids 1–31 being the signal peptide. For details of oxidant treatments, see Section 2. * and
** indicate statistically signiﬁcant diﬀerences to the untreated samples at the p < 0.05 and p < 0.01 levels respectively.
Modiﬁed residue Peptide residues Peptide sequence(s) Modiﬁcation detected Relative site occupancy of modiﬁcations
Treatment
100 μM HOCl 500 μM HOCl MPO /H2O2/Cl-
Tyr-59 58–67 HYQINQQWER 3-ClTyr 0.19*
Trp-65 58–67 HYQINQQWER Trp oxidation 0.24**
Trp-484 480–487 IGDQWDK Trp oxidation 0.15**
Tyr-666 657–669 EATIPGHLNSYTIK 3-ClTyr 1.04*
Tyr-687 673–694 PGVVYEGQLISIQQYGHQEVTR 3-ClTyr 0.14** 1.56** 0.28*
Tyr-687 673–694 PGVVYEGQLISIQQYGHQEVTR 3,5-Cl2Tyr 0.02**
His-689 673–694 PGVVYEGQLISIQQYGHQEVTR His oxidation 0.31**
Met-926 923–938 VTIMWTPPESAVTGYR Met or Trp oxidation 11.74* 40.24**
Trp-927 923–953 VTIMWTPPESAVTGYRVDVIPVNLPGEHGQR
Tyr-937 923–938 VTIMWTPPESAVTGYR 3-ClTyr 0.12*
Tyr-941 940–950 QYNVGPSVSK 3-ClTyr 1.16 0.28**
Tyr-973 / Tyr-974 959–976 NTFAEVTGLSPGVTYYFK 3-ClTyr 0.38** 3.05** 0.63**
Tyr-1062 1055–1070 NLQPASEYTVSLVAIK 3-ClTyr 0.07*
Trp-1195 1170–1197 VVTPLSPPTNLHLEANPDTGVLTVSWER Trp oxidation 2.56**
Tyr-1206 1198–1207 STTPDITGYR 3-ClTyr 3.30** 0.04**
Trp-1468 1452–1476 DLEVVAATPTSLLISWDAPAVTVR Trp oxidation 3.73**
Tyr-1538 1525–1539 GDSPASSKPISINYR 3-ClTyr 0.51**
1533–1539 PISINYR
Trp-1742 1730–1753 FTQVTPTSLSAQWTPPNVQLTGYR Trp oxidation 0.39**
Tyr-1572 1562–1573 WLPSSSPVTGYR 3-ClTyr 1.45** 0.02**
Met-1783 1763–1787 TGPMKEINLAPDSSSVVVSGLMVATK Met oxidation 7.53** 14.48** 16.73**
1767–1787 EINLAPDSSSVVVSGLMVATK
Tyr-1788 1788–1797 YEVSVYALK 3-ClTyr 1.03**
Tyr-1793 1788–1797 YEVSVYALK 3-ClTyr 1.03** 0.14**
Trp-1923 1911–1927 FLATTPNSLLVSWQPPR Trp oxidation 0.18*
Tyr-1879 1867–1880 SYTITGLQPGTDYK 3-ClTyr 0.15*
Tyr-1882 1881–1891 IYLYTLNDNAR 3-ClTyr 0.79* 6.08** 1.73**
Tyr-1882 1881–1891 IYLYTLNDNAR 3,5-Cl2Tyr 0.14** 0.06**
Met-2050 2020–2058 TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFR Met oxidation 26.15**
2020–2059 TPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRR
Tyr-2076 2071–2091 HRPRPYPPNVGEEIQIGHIPR 3-ClTyr 0.64**
Tyr-2302 2301–2310 TYHVGEQWQK 3-ClTyr 0.71** 0.08**
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Fig. 2. Fragment ion spectra from four native and modiﬁed forms of the peptide 923VTIMWTPPESAVTGYR938 from human plasma FN treated with 500 μM HOCl. (A)
Native peptide; (B) single oxidation at Met-926 and to lesser extent at Trp-927; (C) single chlorination of Tyr-937; (D) simultaneous oxidation at Met-926 and
chlorination at Tyr-937. The oxidations result in + 16 Da mass shift on ions y12 (for oxidation at Trp-927) and y13 (for oxidation at Met-926). The chlorination at Tyr-
937 is indicated by the + 34 Da mass shift of the y3 ion. These mass shifts are indicated by the red lines. For fragment ion masses see Supplementary Fig. 3.
Fig. 3. Schematic of the functional domains of
human plasma FN, sites of modiﬁcation
(Table 1) and relative site occupancies (%
modiﬁcation) after treatment with (A) 500 μM
HOCl, or (B) exposure to MPO/H2O2/Cl- with
500 μM H2O2. For further details, see Materials
and methods. M =Met, H =His, W =Trp, Y
=Tyr. Modiﬁcations (m/z+16) detected at
M, H, W are assigned to mono-oxidation.
Modiﬁcations at Y were single or double
chlorinations to give 3-ClTyr or 3,5-Cl2Tyr.
T. Nybo et al. Redox Biology 19 (2018) 388–400
393
total Tyr population present in the FN sequence, by 100 and 500 μM
HOCl respectively (cf. the values of ~ 1.3 and ~ 22.1 described above
for the more limited number of Tyr residues detected in the FN se-
quence by mass spectrometry).
3.3. Increased heparin aﬃnity of HOCl-modiﬁed FN
As modiﬁcations were detected as residues within FN functional
domains (Fig. 3), further analyses were carried out to examine the
potential importance of these modiﬁcations. As multiple modiﬁcations
(Trp-1742, Met-1783, Tyr-1788, Tyr-1793, Tyr-1879, Tyr-1882, Trp-
1923) were detected within the Heparin-II domain (residues
1721–1991), the impact of these modiﬁcations on the ability of FN to
bind heparin was determined by heparin aﬃnity chromatography
(Fig. 5). The elution time of native FN (8.13 min) was signiﬁcantly
shorter from those for FN pre-treated with 100 μM HOCl (8.2 min) or
500 μM HOCl (8.32 min) (Fig. 5), consistent with a stronger binding of
the modiﬁed FN to the heparin molecules present in the column.
3.4. Fibronectin modiﬁed by HOCl or a MPO-H2O2-Cl- system gives rise to
altered adhesion and proliferation of primary human coronary artery
smooth muscle cells (HCASMC)
To examine the impact of oxidant-induced changes on FN, studies
were carried out in which pure cultures of primary human coronary
artery smooth muscle cells (HCASMC) were added to tissue culture
plates containing native or pre-modiﬁed FN. Thus, HCASMC were in-
cubated on native or HOCl-modiﬁed FN for 90min at 37 °C in a cell
incubator before removal of non-adherent cells by washing, and sub-
sequent staining with trypan blue and examination by bright ﬁeld mi-
croscopy (Fig. 6A, top row). Alternatively, cells were added to FN-
coated glass culture slides that had been pre-exposed to HOCl (20 or
100 μM) for 2 h at 37 °C. The adherent HCASMC were then visualized
by staining for F-actin and the nucleus, and ﬂuorescence microscopy
(Fig. 6A, bottom row). The HCASMC showed a characteristic spread
spindle shape on native FN, but were less spread and were typically
“rounded up” on HOCl-treated FN, indicative of poor adherence to
oxidized FN. Quantiﬁcation of cell adherence was carried out using
HCASMC, pre-loaded with the ﬂuorescent dye Calcein-AM, incubated
on native or HOCl-modiﬁed FN (90mins, 37 °C), non-adherent cells
removed by washing, and quantiﬁcation of the number of adherent cell
by ﬂuorescence. Using this approach, and with native FN taken as
100%, a statistically-signiﬁcant decrease in cell adherence was detected
on pre-treatment of the FN with 10 μM or greater concentrations of
HOCl, with this occurring in a dose-dependent manner (Fig. 6B).
Experiments with an MPO-H2O2-Cl- system with 20 nM MPO,
200mM Cl- and varying amounts of H2O2, reproduced the eﬀects of
reagent HOCl. Thus, pre-treatment of FN with the enzyme system de-
creased HCASMC adhesion to the modiﬁed FN, relative to native FN,
with this occurring in a dose-dependent manner with increasing H2O2
Fig. 4. Plots of normalised abundance (+ standard errors), calculated from peptide precursor extracted ion chromatograms from FN after treatment with 0, 100, and
500 μM HOCl for (A) Met-1783 and (C) Tyr-1882, or a MPO/H2O2/Cl- system for (B) Met-1783 and (D) Tyr-1882. Black bars = native untreated samples, white bars
= singly modiﬁed peptides, grey bars = doubly modiﬁed peptides. Met-1783 was identiﬁed in the peptide 1767EINLAPDSSSVVVSGLMVATK1787, and Tyr-1882 in the
peptide 1881IYLYTLNDNAR1891 (Table 1). For further details, see Materials and methods.
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concentrations, with statistical diﬀerences detected at 1 μM or greater
concentrations of H2O2 (Fig. 6C).
Further studies examined the subsequent proliferation of HCASMC
adhered to the native and modiﬁed FN. In these experiments, the cells
were allowed to adhere to the native or HOCl-modiﬁed FN (pre-treated
with 1 μM HOCl to ensure signiﬁcant numbers of adherent cells), and
then allowed to proliferate for 48 h in standard growth medium. After
this period, the number of metabolically active cells was determined
using the MTS assay. Due to the diﬀering initial numbers of cells at the
beginning of the proliferation phase (see data above), the data were
corrected for this parameter by plotting the ﬂuorescence intensity at
day zero against the values obtained from the MTS assay at day 2. The
resulting data (Fig. 7A) show that the gradient of the plots for the
oxidant-modiﬁed FN were greater than that for the native FN (red dots
versus blue dots) indicating that the cells proliferated more rapidly on
the oxidant-treated FN. These data are quantiﬁed in Fig. 7B as a nor-
malised proliferation rate.
3.5. Fibronectin modiﬁed by HOCl or a MPO-H2O2-Cl- system gives rise to
altered gene expression in human coronary artery smooth muscle cells
(HCASMC)
As the data presented above are consistent with decreased ad-
herence, but a subsequent increased rate of HCASMC growth, on oxi-
dant-modiﬁed FN, the expression of a number of mitosis-related genes
were examined in the HCASMC cultured on native versus HOCl-treated
FN. mRNA was collected from cells incubated on the native and mod-
iﬁed FN at day 2 after adhesion (see preceding section) and analysed for
the fold-change in PCNA (Proliferating Cell Nuclear Antigen), CCNA 1
(Cyclin-A1) and CCNB 1 (Cyclin-B1) by RT-PCR with β-actin used as a
housekeeping gene. Signiﬁcantly-elevated levels of these genes were
detected for the cells exposed to the FN pre-treated with all three
concentrations of HOCl examined (1, 10 and 50 μM), compared to na-
tive FN, with the greatest increases (~ 4.7-fold) seen for PCNA after
treatment of the FN with 1 μM HOCl (Fig. 8). Lower, but signiﬁcantly-
elevated expression (~ 3-fold) was detected with higher HOCl con-
centrations. An approximate doubling of the expression of CCNA 1 and
CCNB 1 was seen with all of the FN samples pre-treated with the dif-
ferent HOCl concentrations, with no statistical diﬀerences detected
between the diﬀerent concentrations (Fig. 8).
In addition to changes in mitosis-related genes, potential changes in
the expression of inﬂammation, ECM proteins and ECM-modifying en-
zymes (matrix metalloproteinases, MMPs, and tissue inhibitor of matrix
metalloproteinases 2, TIMP2) were examined for the cells exposed to
the HOCl-modiﬁed FN (as above) compared to native FN. The resulting
data is shown as a heat map relative to the native FN data on a log scale
in Fig. 9.
Exposure of the cells to FN modiﬁed with diﬀerent concentrations of
HOCl (1 μM, 10 μM, 50 μM), compared to native FN, resulted in in-
creased mRNA expression of IL-6 (P < 0.05), with this mirrored by a
small, but signiﬁcant, increase in the level of IL-6 protein, detected by
ELISA, in the conditioned cell media from the cultured HCASMC
(Supplementary Fig. 7), with this occurring in a dose-dependent
manner with increasing HOCl-exposure of the FN. The mRNA levels of
iNOS were also signiﬁcantly elevated (P < 0.05) at all HOCl-con-
centrations tested, whereas only small changes were detected with IL-1β
and COX-2 (Fig. 9).
Gene expression for multiple ECM proteins, including FN and
LAMA1 were signiﬁcantly up-regulated (P < 0.05), while the expres-
sion of LAMB2 was markedly down-regulated (P < 0.05), with these
changes being more marked at the higher concentrations of HOCl (10
and 50 μM) (Fig. 9). Less marked changes were detected in the mRNA
levels of the other matrix proteins examined (Fig. 9). Signiﬁcant up-
regulation of mRNA of a number of MMPs known to be involved in ECM
remodelling, was also detected (Fig. 9). Signiﬁcant increases were de-
tected, particularly for MMP8, MMP11 and MMP13, for HCASMC in-
cubated on FN modiﬁed with 10 μM and 50 μM HOCl, with this ex-
tending down to the 1 μM HOCl treatment for MMPs 11 and 13. These
data are consistent with a range of cellular responses including in-
creased expression of new matrix proteins, and an attempted re-
modelling of the ECM surrounding the cells in response to oxidant-
mediated changes to the FN to which the cells are attached.
Fig. 5. Heparin-aﬃnity chromato-
graphy of human plasma FN (2.27 μM),
either native (no HOCl treatment), or
after modiﬁcation with 100 or 500 μM
HOCl. The peaks in (A) were normal-
ised to equal intensity, and are re-
presentative data. (B) Plot of mean
elution times (+ standard errors) from
3 independent experiments. Black line:
native FN; blue line: treatment with
100 μM HOCl; red line: treatment with
500 μM HOCl. For further details, see
Materials and methods.
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4. Discussion
In this study, we have identiﬁed and quantiﬁed sites of oxidation
and chlorination on the major extracellular matrix protein ﬁbronectin
(FN), induced by the inﬂammatory oxidant HOCl, when added as a
reagent, or generated by a MPO-H2O2-Cl- enzyme system. The plasma
form of FN plays a key role in the early physiological responses to tissue
injury as it binds to ﬁbrin and is a component of blood clots [3]. The
ﬁbrin-FN network is critical to the adhesion, migration and prolifera-
tion of ﬁbroblast and endothelial cells and therefore tissue repair,
Fig. 6. Eﬀect of pre-treatment of FN with HOCl (panels A, B) or MPO/H2O2/Cl-
with the indicated concentrations of H2O2 (panel C), on subsequent adhesion of
primary human coronary artery smooth muscle cells (HCASMC). Panel (A), top
row: HCASMC incubated with trypan blue imaged at 20-fold magniﬁcation
using bright ﬁeld microscopy. Panel (A), bottom row: Adherent cells on native
or HOCl-treated FN stained for F-actin ﬁbres and nuclei and imaged using
ﬂuorescence microscopy. Panels (B, C), Quantiﬁcation of adhewrent HCASMC
pre-loaded with 5 μM calcein AM with subsequent ﬂuorescence detection. For
further details see Materials and methods.
Fig. 7. Eﬀect of pre-treatment of FN with reagent HOCl
(1 μM) on subsequent proliferation of adherent primary
human coronary artery smooth muscle cells (HCASMC).
Panel (A), HCASMC (pre-loaded with 5 μM calcein AM)
were added to untreated FN, or FN pre-treated with 1 μM
HOCl and washed to remove excess oxidant. Adherent
cells were quantiﬁed by ﬂuorescence. The cells were then
incubated for 48 h in growth medium and the ﬁnal cell
population determined by MTS assay. (B) The prolifera-
tion rate of HCASMC for both groups displayed as the ratio
of normalised cell populations at 0 and 48 h. For further
details, see Materials and methods.
Fig. 8. Eﬀect of HOCl-treated FN, compared to parent FN, on mRNA expression
of mitosis-related genes in HCASMC. HCASMC were incubated on native or
HOCl-treated (1, 10 or 50 μM HOCl) ﬁbronectin in 24-well plates for 48 h (as
described in the legend to Fig. 7) before RNA was extracted for cDNA synthesis
and real time PCR. For further details, see Materials and methods.
Fig. 9. Eﬀect of HOCl-treated FN (1, 10 or 50 μM HOCl), compared to parent
FN, on mRNA expression of mitosis-related genes in HCASMC. HCASMC were
incubated on native or HOCl-treated ﬁbronectin for 48 h before RNA extraction,
cDNA synthesis and real time PCR. The heat map indicates changes in expres-
sion on a log scale with green colouration indicating down-regulation, and red
colouration indicating up-regulation. The genes examined include those in-
volved in inﬂammation (purple), extracellular matrix proteins (ECM, yellow)
and matrix metalloproteinases (MMP) and a MMP inhibitor (TIMP-2) (MMP-
related: blue). For further information see main text and Materials and
methods.
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including within the artery wall [4,5]. FN is present in the arterial wall
under normal physiological conditions [7], but increased concentra-
tions, and altered isoforms, are present in atherosclerotic lesions [8]
with this changing during lesion development [9]. Increased lesion FN
levels are mirrored by increases in plasma FN in people with coronary
artery disease [10], with this ascribed to remodelling of the damaged
vascular wall and ECM deposition in the ﬁbrous caps of lesions [11].
The extent of such ECM deposition has been reported to be a critical
factor in lesion stability and propensity to rupture, and therefore the
occurrence of heart attacks and strokes [11]. Previous studies have
provided data consistent with damage to, and destabilization of, com-
ponents of atherosclerotic plaques by oxidants generated by in-
ﬂammatory cells [17,18], with oxidant-mediated damage detected on
ECM perlecan [49,50], laminin [51], (tropo)elastin [52] and ﬁ-
bronectin [53] in human atherosclerotic lesions, as well as lesion li-
poproteins (e.g. [36,37,39,54]). Evidence has been presented a role for
both peroxynitrous acid (ONOOH, from reaction of O2•- with NO•; re-
viewed [55]) as well as MPO-derived HOCl [29,56,57].
Despite the reported importance of ECM damage and lesion desta-
bilization by oxidants, there is limited information on the modiﬁcations
induced by HOCl on isolated FN, or FN in the arterial wall, though it is
well established that FN is a target for HOCl [26–28,57]. There is
however, considerable evidence for the presence of elevated and en-
zymatically active MPO in human atherosclerotic lesions, with this
being localized in regions prone to rupture [23], and modiﬁed FN co-
localizes with MPO in human atherosclerotic lesions [29]. Elevated
MPO levels have been reported, in a large number of studies, to be both
diagnostic and prognostic of major adverse cardiovascular events (e.g.
[25,58–63]).
In addition to altering the composition and structure of FN, oxidant-
damage may also aﬀect FN function, particularly with regard to ECM
assembly, due to the key role that this protein plays in interacting with
other matrix proteins (cf. the ﬁbrin, heparin, and collagen-binding sites
on FN). FN modiﬁcations may also aﬀect cell-ECM interactions due to
the presence of a both a cell binding (RGD) site which interacts with
cellular integrin (α5β1) proteins, and a binding site for vascular en-
dothelial growth factor (VEGF) within the Hep II binding site (in the
III13 and III14 modules) which plays a key role in endothelial cell mi-
gration and proliferation [1]. Recent studies have shown that primary
human coronary artery endothelial cells (HCAEC) show decreased ad-
hesion and proliferation on FN modiﬁed by both HOCl and a MPO-
H2O2-Cl- enzyme system, with this being associated with damage to
speciﬁc FN epitopes including the cell-binding region [57].
HOCl preferentially targets sulfur-containing amino acids (Cys, Met
and cystine) [22,30,31], but can also modify His, Trp, Lys and Tyr re-
sidues to a signiﬁcant extent [22]. The formation of 3Cl-Tyr from re-
action with Tyr residues has been used to elucidate the role of MPO and
HOCl in tissue damage as this product is a stable, distinctive and well-
established biomarker of HOCl-mediated damage [34–36].
The data presented here indicates that both reagent HOCl and the
MPO-H2O2-Cl- system can generate signiﬁcant, but selective, damage
on FN, and that these changes induce signiﬁcant functional alterations
with regard to smooth muscle cell adhesion, proliferation, gene ex-
pression and phenotype. The enzyme system was provided with 500 μM
H2O2 in order to generate ~ 500 μM HOCl to allow direct comparison
between the reagent and enzyme systems, and hence any potential lo-
calization or other eﬀects induced by the enzyme.
Of the residues expected to react with HOCl and MPO-H2O2-Cl-
system [22,30,64], a high proportion were present in the peptide se-
quences detected by the MS mapping. Of the 26 Met residues present in
the human plasma FN sequence (UniProt – P02751), 14 were observed
by MS, with 27 of 39 detected for Trp, 33 from 55 for His, and 64 from
100 for Tyr. Of these residues only 3 Met, 7 Trp, 1 His and 16 Tyr
residues were detected as targets for oxidation (in the case of Met, Trp
and His) or chlorination (Tyr), when exposed to reagent HOCl (100 or
500 μM) or the MPO-H2O2-Cl- system. This corresponds to modiﬁcation
levels of ~11.5, ~12.8, ~2.0 and ~15.0% for Met, Trp, His and Tyr
respectively when considered as a % of the full sequence total, and
~21.4, ~25.9, ~3.0 and ~23.4%, respectively, of the Met, Trp, His and
Tyr residues detected. The similarity of these percentages for Met, Trp
and Tyr, suggest that factors other than the absolute reactivity of a
particular type of residue with HOCl (which decreases in the order
Met> >Trp>Tyr; [22,30,64]) must play a role in determining
which sites are modiﬁed.
Summation of the extents of 3-ClTyr formation detected by both MS
and the amino acid analyses, indicates that between 13% and 22% of
the Tyr residues are modiﬁed by 500 μM HOCl, and hence ~ 1 in 5 FN
molecules contains a 3Cl-Tyr residue after this treatment. The overall
extent of modiﬁcation (i.e. including oxidation) was considerably
higher (primarily driven by the high extent of Met modiﬁcation), with
~ 1 in 5 FN molecules carrying a modiﬁcation after treatment with
100 μM HOCl or the MPO system, and all (~ 110%) FN molecules, on
average, containing a single modiﬁcation after treatment with 500 μM
HOCl.
These site occupancy data indicate that only a subset of the residues
detected by MS are detected in a modiﬁed form, and hence it is likely
that some residues are much more susceptible to modiﬁcation than
others. Therefore, as the sequence coverage was only ~ 66%, there may
be modiﬁcations to signiﬁcantly more residues within the non-detected
portions of the sequence. However the relative similarity of the data
between the MS and total amino acid analyses suggest that a reasonably
similar extent of modiﬁcation must also be occurring in the non-ob-
served regions of the sequence. Most of the “missing” sequence is
comprised of the cystine (disulﬁde)-rich Hep I/Fibrin I, Collagen, and
Fibrin II domains of FN. These regions are diﬃcult to detect using the
current protocol as a result of the absence of a reduction and alkylation
steps which remove the disulﬁde bonds and thereby release these
peptides. This protocol was however employed as reduction and alky-
lation have been shown to cause artefactual loss of modiﬁcation sites
([48]; T. Nybo, M.J. Davies, A. Rogowska-Wrzesinska, unpublished
data).
Comparison of the data obtained with 500 μM HOCl and the MPO
system shows a similar pattern of chlorination but fewer sites, and
lower extents, of modiﬁcation, with only 8 of the 16 Tyr chlorinations
seen with HOCl, reproduced by the MPO system. Oxidation was ob-
served at 4 residues with the enzyme system (2 × Trp, 1 × His, 1 ×
Met) compared to 7 with HOCl, though the position and nature of the
residues aﬀected were signiﬁcantly diﬀerent for the oxidized residues
when compared to the chlorination sites (Table 1). These ﬁndings in-
dicate that there are diﬀerences in the selectivity of damage between
reagent HOCl and the enzyme system with regard to the susceptibility
of certain sites to modiﬁcation. The overall extent of modiﬁcation was
also lower for the MPO system than reagent HOCl; this is perhaps un-
derstandable due to the presence of additional protein in the enzyme
system (in the form of the MPO), which will also be a target for HOCl.
Indeed, a number of MPO-derived peptides containing oxidation sites
were detected in the enzyme experiments, though these were not ana-
lysed in detail (Nybo et al., unpublished data).
The reasons for the (apparent) altered speciﬁcity of damage ob-
served with the enzyme system is unclear. The majority of the diﬀer-
ences are present in the N-terminal portion of FN, which appears to be
exclusively modiﬁed by the MPO-system, with this possibly due to as-
sociation of the enzyme with one or more domains within this part of
FN. Thus, oxidation of Trp-65 and Trp-484 were detected in the I1 and
I7, modules, while oxidation at His-689 was also detected in module
III1. Furthermore, the absence of signiﬁcant modiﬁcation of Met-926 by
the MPO system, which is signiﬁcantly modiﬁed by reagent HOCl, is
consistent with an altered conformation or accessibility of this residue
in the presence of MPO, compared to its absence. It has been reported
previously that MPO binds to FN [65], though MPO activity was re-
ported to increase after binding to FN in cell-derived ECM [65,66], and
the exact site of interaction has not been established. Our observations
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implicate the N-terminal region.
The MPO-speciﬁc oxidation site, Trp-65, is located in loop 1 within
the ﬁbrin binding site [67] (Fig. 10). This observation is of potential
signiﬁcance, as a previous study has shown that chemical modiﬁcation
of Trp residues in this domain caused a 90% loss of heparin binding
compared to unmodiﬁed controls [68]. Binding of ﬁbrin/ﬁbrinogen
plays a key role in thrombus formation important in wound healing and
stabilisation of atherosclerotic lesions [16,69,70].
For both the reagent and enzymatic systems, the Hep II domain was
heavily modiﬁed with two major targets and other lesser sites of
modiﬁcation. The most heavily modiﬁed sites (Met-1783, detected as a
+16m/z species; and Tyr-1882, detected as both a mono- and di-
chlorinated species) are surface exposed in a partial crystal structure of
this domain (Fig. 10) [71]. These alterations appear to induce a higher
binding aﬃnity of the modiﬁed FN towards heparin than the un-
modiﬁed form, as judged by the increased retention on the heparin
column.
Cell adhesion to FN is mediated, at least in part, via interactions
with cell-surface integrins, and particularly α5β1, with the RGD motif
present in the cell-binding domain (module III10) [72]. This interaction
appears to be only suﬃcient for attachment and spreading of the cells,
with additional interactions and signalling involving syndecan-4 re-
quired for focal adhesion formation, and the arrangement of the actin
cytoskeleton into bundled stress ﬁbres [73,74]. The signalling induced
by these focal adhesions is a prerequisite for gene expression, cell cycle
regulation, and control of apoptosis [75]. Syndecan-4 interacts with the
Hep II domain of FN through heparin sulfate chains with speciﬁc
properties [76], and activates protein kinase C-α signalling [77] in the
presence of inositol phospholipids (reviewed [78,79]). Recent data also
indicates that the Hep II domain is a binding domain for vascular en-
dothelial cell growth factor (VEGF), and that bound VEGF “talks” to the
cell-binding domain, with both domains required for cell adherence,
proliferation and migration of endothelial cells and osteoblasts [80,81].
In the current studies, two modiﬁcations were detected in the cell-
binding domain (Trp-1468, Tyr-1538) with 500 μMHOCl. Both residues
are distant (within the sequence) from the RGD site (residues
1524–1526), and are modiﬁed to only a moderate (Trp-1468) or low
extent (Tyr-1538). It is therefore impossible to determine whether these
modiﬁcations are responsible, possibly via remotely-induced con-
formational changes, for the decreased HCASMC adherence observed in
the current study. However, it is possible that these alterations, in
conjunction with those in the Hep II region, may be suﬃcient to explain
the observed decrease in cell adhesion.
The enhanced proliferation and altered gene expression detected for
the HCASMC after initial adherence may also arise from the modiﬁca-
tions in the Hep II domain, as this domain modulates cell signalling and
cell cycle control [75]. The increased expression in PCNA, CCNA 1 and
CCNB 1 in HCASMC exposed to HOCl-modiﬁed FN is consistent with
the enhanced rate of cell growth detected for cells on modiﬁed com-
pared to control FN. Modiﬁed FN also induced alterations in the ex-
pression of genes associated with ECM synthesis and remodelling, with
upregulation of some matrix proteins (e.g. LAMA1), a decrease in others
(e.g. LAMB2), and upregulation of the expression of multiple MMPs.
Increased expression of inﬂammatory genes, and particularly iNOS and
IL-6, were also detected, with higher expression of the latter reﬂected in
increased IL-6 protein excretion. Together these data suggest that
modiﬁed FN generates phenotypic changes in adherent HCASMC with
these having proliferative and pro-inﬂammatory characteristics.
These changes are of potential biological signiﬁcance as it is well
established that during the development of atherosclerotic lesions,
medial smooth muscle cells switch from a quiescent contractile phe-
notype to a migratory and proliferative form. The latter migrate into the
growing lesion, aided via a disruption of the elastic lamina (arising from
either direct oxidation or MMP-mediated), and play an important role
in generating the ﬁbrous cap of the lesion via ECM synthesis. The as-
sembly of newly-synthesized ECM by such cells may also be of critical
importance, as highly ﬁbrous lesions are less prone to rupture and
thrombus formation. In this respect, it is interesting to note that one of
the other modiﬁcations detected, at Tyr-666 (observed as 3-ClTyr) in
the anastellin domain, is critical to superﬁbronectin formation and ﬁ-
bril assembly [1]. Mutation of this Tyr, together with Leu-663 to Ala,
abolishes polymerization activity [82], without aﬀecting FN secondary
structure, ﬁbronectin binding, or p38 kinase activation [82,83]. It is
therefore possible that the synthesis and assembly of new FN ﬁbres by
HCASMC, in the presence of HOCl-modiﬁed FN, may be incomplete or
modulated as a result of the Tyr-666 chlorination. Altered FN ﬁbre
assembly may have downstream consequences, as correct FN ﬁ-
brillogenesis is a requirement for the correct deposition of other ECM
materials including ﬁbrillin-1 microﬁbrils [84] and collagen-containing
structures [85]. The modiﬁcations to FN may therefore result in a
weakened or modiﬁed ECM structure in lesions.
Overall, these data provide novel insights into how damage induced
by MPO and its oxidants, can change the ECM environment and have
consequent eﬀects on associated cells. Using MS-based quantiﬁcation of
site-speciﬁc amino acid modiﬁcations we have shown that MPO-gen-
erated HOCl modiﬁes selected regions in FN, with damage observed in
functional domains, including damage clusters within the heparin-
binding sequence. The modiﬁed FN exhibits increased binding aﬃnity
for heparin. Human coronary artery smooth muscle cells (HCASMC)
show decreased adherence, increased proliferation and growth, and
altered gene expression in response to modiﬁed FN, with increased
expression of genes involved in ECM formation and remodelling. These
ﬁndings indicate that modiﬁed FN may play a major role in the for-
mation, development and stabilisation of ﬁbrous caps in atherosclerotic
lesions.
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